(231 days)
Not Found
No
The description focuses on the mechanical components and function of a physical filter system, with no mention of AI/ML, image processing, or data analysis.
Yes.
The device is intended for "embolic particulate capture," which is a therapeutic intervention to prevent emboli from causing further damage during PTCI. The description also explicitly states it is used "in conjunction with other therapeutic devices."
No
The device is described as a coronary filter system intended for embolic particulate capture during PTCI, which is a therapeutic function, not a diagnostic one.
No
The device description clearly outlines multiple hardware components, including a filter, handle, guidewire, and catheters. There is no mention of software as a component or the primary function of the device.
Based on the provided text, the Mcdtronic Interceptor® PLUS Coronary Filter System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly states it's for use in saphenous vein bypass grafts during percutaneous transluminal coronary intervention (PTCI) for embolic particulate capture. This describes a device used within the body during a medical procedure, not a device used to test samples outside the body.
- Device Description: The description details a physical system with a filter, guidewire, and other components designed to be inserted into a blood vessel. This is consistent with an interventional medical device.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.), performing tests on these samples, or providing diagnostic information based on such analysis.
Therefore, the Mcdtronic Interceptor® PLUS Coronary Filter System is an interventional medical device, not an IVD.
N/A
Intended Use / Indications for Use
The Mcdtronic Interceptor® PLUS Coronary Filter System is intended for use in saphenous vein bypass grafts, with a reference vessel diameter between 2.5 mm and 5.25mm, in conjunction with percutaneous transluminal coronary intervention (PTCI) for embolic particulate capture. The Interceptor® PLUS Coronary Filter System is intended for temporary use in conjunction with other therapeutic devices and is intended to be removed at the completion of the interventional procedure.
Product codes (comma separated list FDA assigned to the subject device)
NFA
Device Description
The Interceptor® PLUS Coronary Filter System (the Device) consists of six components; an 180cm extendable Steerable Vascular Filter, an Actuator Handle, a Torque Handle, a Guidewire Introducer, Peel Away Introducer and a RX Facilitator Catheter . The Steerable Vascular Filter is comprised of a radiopaque nitinol filter mounted near the distal tip of a steerable 0.014 inch nitinol hypotube guidewire. The guidewire extends 3.5cm beyond the distal end of the filter in the collapsed state to facilitate distal tracking and steering through tortuous vessels and tight lesions. The proximal end of the steerable vascular filter contains four large openings (Approximately 1400 microns for the 3.5mm filter, >1500 microns for the 4.5mm filter size and >1800 microns for the 5.5mm filter size) that allow embolic particulate to enter the filter.
In addition to the Interceptor® PLUS Coronary Filter System, there is an optional Angled RX Facilitator Catheter when an alternative tip configuration is desired for filter withdrawal.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
saphenous vein bypass grafts
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A Clinical evaluation, AMEthyst study, was conducted in a randomized clinical trial involving a total of 800 saphenous vein graft patients. Patients were enrolled and randomized to one of two groups (Treatment )Interceptor or Interceptor PLUS Coronary Filter System] or the Control [GuardWire® Temporary Occlusion Balloon and Aspiration System or FilterWire EZTM Embolic Protection System]) at an unbalanced 2:1 ratio. The primary endpoint of this trial was Major Adverse Cardiac Events (MACE) related to the target vessel at 30 days: defined as death, Q-wave or non-Q wave MI, emergent coronary artery bypass surgery, or target vessel revascularization within 30 days of the index procedure. The primary endpoint analysis resulted in a MACE rate of 8.0% (40/501) in the Treatment arm and 7.3% (18/247) in the Control arm which demonstrates non-inferiority when tested to a delta of 4.5%. The upper 95% confidence interval of the difference between the two groups was 4.0%.
During the conduct of the AMFithyst study there were 163 Treatment (Interceptor and Interceptor PLUS) patients and 82 Control (GuardWire and FilterWire) patients who had at least one missing CK-MB result. To address this issue of missing CK-MB data an additional analysis on MACE was performed to determine a statistical estimate regarding the number of patients who may have experienced a non-Q wave MI. For the purposes of the analysis Interceptor subjects were excluded from the Treatment group and only Interceptor PLUS subjects were analyzed resulting in 139 patients. The number of Control patients remained 82. Data from 158 patients in the GuardWire arm of the SAFER study and 178 patients in the Control arm form the Amethyst study with non-missing CK-MB at all three time points (6-8, 12-16, and 18-24) were used in conjunction with conditional probability theory to estimate the number of non-Q wave MI that could have resulted for each of the various missing data patterns. The probabilities of a non-Q Wave MI for the Interceptor PLUS arm was based on the probabilities calculated for the SAFER study. The probabilities of this event in the Control arm were based on the Control Arm of the Amethyst study. For the Interceptor PLUS group, the total expected number of additional patients with non-Q wave MI was 2.392. For the Control group, the total expected number of additional patients with non-Q wave MI was 2.077. Taking a conservative approach and assuming 3 additional Interceptor PLUS patients experienced 30day MACE, versus only 2 in the control group, the rate of MACE at 30 days would increase from 8.4% to 9.1% for Interceptor PLUS arm and from 7.3% to 8.1% for the Control arm. The resulting non-inferiority p-value on the Interceptor PLUS vs. Control risk difference, using an absolute non-inferiority margin of 4.5%, is 0.050, allowing non-inferiority of Interceptor Plus to Control to be claimed.
Based on acute procedural and 30-day clinical results, the Interceptor PLUS Coronary Filter System has demonstrated non-inferior safety and efficacy compared with the GuardWire Temporary Occlusion Balloon and Aspiration System and the FilterWire EZ Embolic Protection System.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
MACE rate of 8.0% (40/501) in the Treatment arm and 7.3% (18/247) in the Control arm, non-inferiority when tested to a delta of 4.5%. The upper 95% confidence interval of the difference between the two groups was 4.0%.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K061332, K052280, K063785, K013913, K023878
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).
0
AUG - 1 2008
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS (Pursuant to Section 12, Safe Medical Devices Act of 1990)
-
- Identifying Information:
| Submitter: | Medtronic Vascular
37A Cherry Hill Drive
Danvers, MA 01923 |
|-----------------|------------------------------------------------------------------------|
| Contact Person: | Colleen Mullins
Sr. Regulatory Affairs Specialist
(978) 739-3267 |
-
- Classification Name: Device, Coronary Saphenous Vein Bypass Graft, Temporary, For Embolization Protection (21 CFR Part 870.1250) Product Code NFA
- Proprietary Name: 3. Interceptor® PLUS Coronary Filter System
4. Name of Predicate Devices:
| FilterWire EZ TM Embolic Protection System (2.25mm-3.5mm) | K061332 |
|---|---|
| FilterWire EZTM Embolic Protection System | K052280 |
| SpiderFXTM Embolic Protection Device | K063785 |
| PercuSurge GuardWire Temporary Occlusion and Aspiration System | K013913 |
| GuardWire 3-6 Temporary Occlusion and Aspiration System | K023878 |
1
5. Description:
The Interceptor® PLUS Coronary Filter System (the Device) consists of six components; an 180cm extendable Steerable Vascular Filter, an Actuator Handle, a Torque Handle, a Guidewire Introducer, Peel Away Introducer and a RX Facilitator Catheter . The Steerable Vascular Filter is comprised of a radiopaque nitinol filter mounted near the distal tip of a steerable 0.014 inch nitinol hypotube guidewire. The guidewire extends 3.5cm beyond the distal end of the filter in the collapsed state to facilitate distal tracking and steering through tortuous vessels and tight lesions. The proximal end of the steerable vascular filter contains four large openings (Approximately 1400 microns for the 3.5mm filter, >1500 microns for the 4.5mm filter size and >1800 microns for the 5.5mm filter size) that allow embolic particulate to enter the filter.
In addition to the Interceptor® PLUS Coronary Filter System, there is an optional Angled RX Facilitator Catheter when an alternative tip configuration is desired for filter withdrawal.
Intended-Üse: 6.
The Interceptor® PLUS Coronary Filter System is intended for use in saphenous vein bypass grafts, with a reference vessel diameter between 2.5 mm and 5.25mm, in conjunction with percutaneous transluminal coronary intervention (PTCI) for embolic particulate capture. The Interceptor® PLUS Coronary Filter System is intended for temporary use in conjunction with other therapeutic devices and is intended to be removed at the completion of the interventional procedure.
156
2
7. Summary Of Substantial Equivalence:
The Interceptor® PI.US Coronary Filter System for use in saphenous vein bypass grafts, is equivalent to the following predicate devices in that the intended use, principles of operation, design and materials are similar:
| FilterWire EZ™ Embolic Protection System (2.25mm-3.5mm) | K061332 |
|---|---|
| FilterWire EZ™ Embolic Protection System | K052280 |
| SpiderFX™ Embolic Protection Device | K063785 |
| PercuSurge GuardWire Temporary Occlusion and Aspiration System | K013913 |
| GuardWire 3-6 Temporary Occlusion and Aspiration System | K023878 |
Summary of Safety and Performance: 8.
A Clinical evaluation, AMEthyst study, was conducted in a randomized clinical trial involving a total of 800 saphenous vein graft patients. Patients were enrolled and randomized to one of two groups (Treatment )Interceptor or Interceptor PLUS Coronary Filter System] or the Control [GuardWire® Temporary Occlusion Balloon and Aspiration System or FilterWire EZTM Embolic Protection System]) at an unbalanced 2:1 ratio. The primary endpoint of this trial was Major Adverse Cardiac Events (MACE) related to the target vessel at 30 days: defined as death, Q-wave or non-Q wave MI, emergent coronary artery bypass surgery, or target vessel revascularization within 30 days of the index procedure. The primary endpoint analysis resulted in a MACE rate of 8.0% (40/501) in the Treatment arm and 7.3% (18/247) in the Control arm which demonstrates non-inferiority when tested to a delta of 4.5%. The upper 95% confidence interval of the difference between the two groups was 4.0%.
3
Notc: During the conduct of the AMFithyst study there were 163 Treatment (Interceptor and Interceptor PLUS) patients and 82 Control (GuardWire and FilterWire) patients who had at least one missing CK-MB result. To address this issue of missing CK-MB data an additional analysis on MACE was performed to determine a statistical estimate regarding the number of patients who may have experienced a non-Q wave MI. For the purposes of the analysis Interceptor subjects were excluded from the Treatment group and only Interceptor PLUS subjects were analyzed resulting in 139 patients. The number of Control patients remained 82. Data from 158 patients in the GuardWire arm of the SAFER study and 178 patients in the Control arm form the Amethyst study with non-missing CK-MB at all three time points (6-8, 12-16, and 18-24) were used in conjunction with conditional probability theory to estimate the number of non-Q wave MI that could have resulted for each of the various missing data patterns. The probabilities of a non-Q Wave MI for the Interceptor PLUS arm was based on the probabilities calculated for the SAFER study. The probabilities of this event in the Control arm were based on the Control Arm of the Amethyst study. For the Interceptor PLUS group, the total expected number of additional patients with non-Q wave MI was 2.392. For the Control group, the total expected number of additional patients with non-Q wave MI was 2.077. Taking a conservative approach and assuming 3 additional Interceptor PLUS patients experienced 30day MACE, versus only 2 in the control group, the rate of MACE at 30 days would increase from 8.4% to 9.1% for Interceptor PLUS arm and from 7.3% to 8.1% for the Control arm. The resulting non-inferiority p-value on the Interceptor PLUS vs. Control risk difference, using an absolute non-inferiority margin of 4.5%, is 0.050, allowing non-inferiority of Interceptor Plus to Control to be claimed.
Based on acute procedural and 30-day clinical results, the Interceptor PLUS Coronary Filter System has demonstrated non-inferior safety and efficacy compared with the GuardWire Temporary Occlusion Balloon and Aspiration System and the FilterWire EZ Embolic Protection System.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES . USA" are arranged in a circular pattern around the eagle. The eagle is black, and the text is also black. The logo is simple and recognizable.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG - 1 2008
Medtronic Vascular c/o Ms. Colleen Mullins Senior Regulatory Affairs Specialist 37 A Cherry Hill Drive Danvers, MA 01923
Re: K073523
Trade/Device Name: Interceptor® PLUS Coronary Filter System Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: NFA Dated: June 30, 2008 Received: July 1, 2008
Dear Ms. Mullins:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality
5
Page 2 - Ms. Colleen Mullins
systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entifled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Dona R. Vachner
A Bram D. Zuckerman, M.D. - Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number: K073523
Device Name: Interceptor® PLUS Coronary Filter System
Indications for Use:
The Mcdtronic Interceptor® PLUS Coronary Filter System is intended for use in saphenous vein bypass grafts, with a reference vessel diameter between 2.5 mm and 5.25mm, in conjunction with percutaneous transluminal coronary intervention (PTCI) for embolic particulate capture. The Interceptor® PLUS Coronary Filter System is intended for temporary use in conjunction with other therapeutic devices and is intended to be removed at the completion of the interventional procedure.
The safety and effectiveness of this device as an embolic protection system has not been established in the cerebral, carotid, or peripheral vasculature
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Duane R. Barnes
(Division Sign-Off) Division of Cardiovascular Devices
510(k) Number_Ko73523
Page 1 of 1